3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
13
Prostatic Neoplasms
4
Carcinoma, Hepatocellular
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Neoplasms
3
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Sarcoma, Ewing
2
Penile Neoplasms
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Melanoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Clear-cell metastatic renal cell carcinoma
2
Central Nervous System Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Medullary
2
Carcinoma
2
Adrenocortical Carcinoma
2
von Hippel-Lindau Disease
1
Wilms Tumor
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Interventions
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
cabozantinib
×
30 days
×
Clear all
No trials found.